晚期帕金森病治疗的新进展

被引：5

作者：

刘忠伟

机构：

[1] 吉林省吉林市人民医院

来源：

中国医药科学 | 2015年 / 5卷 / 24期

关键词：

晚期帕金森病; 运动障碍; 运动并发症;

D O I：

暂无

中图分类号：

R742.5 [震颤麻痹综合征];

学科分类号：

100204 [神经病学];

摘要：

晚期帕金森病是指帕金森病的后期阶段,或Hoehn和Yahr评分量表的第4和第5阶段,目前尚无确切的定义标准,但临床工作者通常将对药物治疗反应不佳,药物疗效维持时间缩短,或需要加大单药剂量和需要联合2,3,4种不同药物才能达到疗效的帕金森病患者定义为晚期帕金森病。另一些学者认为把出现运动并发症作为晚期帕金森病的定义标准更为准确。本文晚期帕金森病的定义标准为:尽管有积极的药物和行为学管理措施,依然发生运动并发症。对晚期帕金森病运动和非运动并发症的治疗管理日趋复杂,适当的支持性护理变得越来越重要,本文将对晚期帕金森病运动和非运动并发症的治疗管理进行循证评价。

引用

页码：31 / 34

页数：4

共 12 条

[1]

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial [J].

Cummings, Jeffrey ;

Isaacson, Stuart ;

Mills, Roger ;

Williams, Hilde ;

Chi-Burris, Kathy ;

Corbett, Anne ;

Dhall, Rohit ;

Ballard, Clive .

LANCET, 2014, 383 (9916) :533-540

[2]

Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease – A randomized study.[J].S. Rios Romenets;L. Creti;C. Fichten;S. Bailes;E. Libman;A. Pelletier;R.B. Postuma.Parkinsonism and Related Disorders.2013, 7

[3]

Adenosine A<sub>2A</sub> receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.[J].Yoshikuni Mizuno;Tomoyoshi Kondo;.Mov Disord..2013, 8

[4]

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study [J].

Olanow, C. Warren ;

Kieburtz, Karl ;

Odin, Per ;

Espay, Alberto J. ;

Standaert, David G. ;

Fernandez, Hubert H. ;

Vanagunas, Arvydas ;

Othman, Ahmed A. ;

Widnell, Katherine L. ;

Robieson, Weining Z. ;

Pritchett, Yili ;

Chatamra, Krai ;

Benesh, Janet ;

Lenz, Robert A. ;

Antonini, Angelo .

LANCET NEUROLOGY, 2014, 13 (02) :141-149

[5]

Extended-release pramipexole in advanced Parkinson disease A randomized controlled trial [J].

Schapira, A. H. V. ;

Barone, P. ;

Hauser, R. A. ;

Mizuno, Y. ;

Rascol, O. ;

Busse, M. ;

Salin, L. ;

Juhel, N. ;

Poewe, W. .

NEUROLOGY, 2011, 77 (08) :767-774

[6]

Treatment of dysautonomia associated with Parkinson's disease.[J].Giovanni Mostile;Joseph Jankovic.Parkinsonism and Related Disorders.2009,

[7]

Patient profile; indications; efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease<link href="#fn1"/> <link href="#fn2"/>.[J].David Devos;.Mov. Disord..2009, 7

[8]

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease [J].